Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients : A systematic review and meta-analysis
© 2022 The Authors. Oral Diseases published by Wiley Periodicals LLC..
Head and neck squamous cell carcinoma (HNSCC) is among the common tumors associated with high mortality. The aim of our meta-analysis was to determine how additional anti-epidermal growth factor receptor (EGFR) therapy to standard chemotherapy affects the progression-free (PFS) and overall survival (OS) of the patients, besides the most common side effects. We used CENTRAL, MEDLINE, and Embase databases until October 26, 2020, and included 13 eligible randomized controlled trials in our systematic research. The pooled hazard ratios (HR) for the main outcomes from the original data were estimated and for the other dichotomous outcomes, odds ratios (ORs) with their 95% confidence intervals (CI) were calculated. Addition of EGFR inhibitors to conventional chemotherapy significantly decreased the death and disease progression (for PFS HR: 0.68, 95% CI: 0.55-0.81, I2 = 65.5%, p = 0.005) and mortality (for OS HR: 0.83, 95% CI: 0.72-0.94, I2 = 42.3%, p = 0.076). In the EGFR inhibitor group, we revealed an increased chance of the over Grade 3 skin rashes (OR: 4.86; 95% CI: 1.52-15.49, I2 = 2.3%, p = 0.407), and all Grade skin rashes (OR: 18.32, 95% CI: 8.07-41.60, I2 = 56.6%, p = 0.032). Despite their unwanted dermatological side effects, the addition of EGFR inhibitors is recommended to be included in advanced HNSCC therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Oral diseases - 29(2023), 5 vom: 27. Juli, Seite 1905-1919 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kiss, Fruzsina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.06.2023 Date Revised 12.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/odi.14228 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340148136 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340148136 | ||
| 003 | DE-627 | ||
| 005 | 20231226004503.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/odi.14228 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1133.xml |
| 035 | |a (DE-627)NLM340148136 | ||
| 035 | |a (NLM)35485982 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kiss, Fruzsina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Addition of epidermal growth factor receptor inhibitors to standard chemotherapy increases survival of advanced head and neck squamous cell carcinoma patients |b A systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.06.2023 | ||
| 500 | |a Date Revised 12.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Oral Diseases published by Wiley Periodicals LLC. | ||
| 520 | |a Head and neck squamous cell carcinoma (HNSCC) is among the common tumors associated with high mortality. The aim of our meta-analysis was to determine how additional anti-epidermal growth factor receptor (EGFR) therapy to standard chemotherapy affects the progression-free (PFS) and overall survival (OS) of the patients, besides the most common side effects. We used CENTRAL, MEDLINE, and Embase databases until October 26, 2020, and included 13 eligible randomized controlled trials in our systematic research. The pooled hazard ratios (HR) for the main outcomes from the original data were estimated and for the other dichotomous outcomes, odds ratios (ORs) with their 95% confidence intervals (CI) were calculated. Addition of EGFR inhibitors to conventional chemotherapy significantly decreased the death and disease progression (for PFS HR: 0.68, 95% CI: 0.55-0.81, I2 = 65.5%, p = 0.005) and mortality (for OS HR: 0.83, 95% CI: 0.72-0.94, I2 = 42.3%, p = 0.076). In the EGFR inhibitor group, we revealed an increased chance of the over Grade 3 skin rashes (OR: 4.86; 95% CI: 1.52-15.49, I2 = 2.3%, p = 0.407), and all Grade skin rashes (OR: 18.32, 95% CI: 8.07-41.60, I2 = 56.6%, p = 0.032). Despite their unwanted dermatological side effects, the addition of EGFR inhibitors is recommended to be included in advanced HNSCC therapy | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a EGFR inhibitors | |
| 650 | 4 | |a head and neck squamous cell carcinoma | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a progression-free survival | |
| 650 | 4 | |a safety profile | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Pohóczky, Krisztina |e verfasserin |4 aut | |
| 700 | 1 | |a Görbe, Anikó |e verfasserin |4 aut | |
| 700 | 1 | |a Dembrovszky, Fanni |e verfasserin |4 aut | |
| 700 | 1 | |a Kiss, Szabolcs |e verfasserin |4 aut | |
| 700 | 1 | |a Hegyi, Péter |e verfasserin |4 aut | |
| 700 | 1 | |a Szakó, Lajos |e verfasserin |4 aut | |
| 700 | 1 | |a Tóth, Lilla |e verfasserin |4 aut | |
| 700 | 1 | |a Ezer, Éva Somogyiné |e verfasserin |4 aut | |
| 700 | 1 | |a Szalai, Eszter |e verfasserin |4 aut | |
| 700 | 1 | |a Helyes, Zsuzsanna |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral diseases |d 1995 |g 29(2023), 5 vom: 27. Juli, Seite 1905-1919 |w (DE-627)NLM075295946 |x 1601-0825 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:5 |g day:27 |g month:07 |g pages:1905-1919 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/odi.14228 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 5 |b 27 |c 07 |h 1905-1919 | ||